{
    "clinical_study": {
        "@rank": "120917", 
        "arm_group": [
            {
                "arm_group_label": "Pelubiprofen", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Loxoprofen", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Multi-center, Randomized, Double blind, Controlled Parallel-group Comparative Phase 3\n      Clinical trial to assess the efficacy and safety of Pelubiprofen Compared to Loxoprofen in\n      patients with Acute upper respiratory infection."
        }, 
        "brief_title": "Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection", 
        "condition": [
            "Acute Upper Respiratory Infection", 
            "Fever"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fever", 
                "Respiratory Tract Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Over 15 years old\n\n          2. Male and Female\n\n          3. Patients with fever over 38.0\u00b0C due to cold (acute upper respiratory tract infection)\n\n          4. Patients with upper respiratory tract infection outbreak within 2 days and who did\n             not received drug administration\n\n          5. Subjects who voluntarily or legal guardian agreed with written consent\n\n        Exclusion Criteria:\n\n          1. Fever reducer administration Within 4 hours from the screening point\n\n          2. Any incidence of febrile crisis from the past six months\n\n          3. Patinets with Ulcers, gastrointestinal disorders which are confirmed by endoscopy\n\n          4. Patinets with continuously administrating gastrointestinal disorder related drug\n\n          5. Patients with severe blood damage\n\n          6. Severe hepatic impairment (ALT, AST value more than 2 times the upper limit of the\n             normal range)\n\n          7. With severe renal impairment (serum creatinine value is more than 2 times the upper\n             limit of the normal range)\n\n          8. Patients with severe left ventricular dysfunction"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "firstreceived_date": "January 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779271", 
            "org_study_id": "Plb CD 301 Version 3.10"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pelubiprofen", 
                "intervention_name": "Pelubiprofen", 
                "intervention_type": "Drug", 
                "other_name": "Pelubiprofen 30 mg"
            }, 
            {
                "arm_group_label": "Loxoprofen", 
                "intervention_name": "Loxoprofen", 
                "intervention_type": "Drug", 
                "other_name": "Loxoprofen 60mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Loxoprofen"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pelubi", 
            "Pelubiprofen", 
            "Loxoprofen", 
            "Anti-pyretic", 
            "Fever"
        ], 
        "lastchanged_date": "February 10, 2014", 
        "location": {
            "contact": {
                "last_name": "Byung-Hui Choi, pf.", 
                "phone": "+82 02-6299-2738"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Chung-Ang University Hospital, South Korea"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Changes in Body temperature from baseline", 
            "time_frame": "0, 0.5, 1, 1.5, 2, 3, 4, 6 Hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779271"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Daewon Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daewon Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}